Analysis of responder-based endpoints: improving power through utilising continuous components. by Wason, James et al.
RESEARCH Open Access
Analysis of responder-based endpoints:
improving power through utilising
continuous components
James Wason1,2* , Martina McMenamin2 and Susanna Dodd3
Abstract
Background: Clinical trials and other studies commonly assess the effectiveness of an intervention through the use
of responder-based endpoints. These classify patients based on whether they meet a number of criteria which
often involve continuous variables categorised as being above or below a threshold. The proportion of patients
who are responders is estimated and, where relevant, compared between groups. An alternative method called the
augmented binary method keeps the definition of the endpoint the same but utilises information contained within
the continuous component to increase the power considerably (equivalent to increasing the sample size by > 30%).
In this article we summarise the method and investigate the variety of clinical conditions that use endpoints to
which it could be applied.
Methods: We reviewed a database of core outcome sets (COSs) that covered physiological and mortality trial
endpoints recommended for collection in clinical trials of different disorders. We identified responder-based
endpoints where the augmented binary method would be useful for increasing power.
Results: Out of the 287 COSs reviewed, we identified 67 new clinical areas where endpoints were used that would
be more efficiently analysed using the augmented binary method. Clinical areas that had particularly high numbers
were rheumatology (11 clinical disorders identified), non-solid tumour oncology (10 identified), neurology (9
identified) and cardiovascular (8 identified).
Conclusions: The augmented binary method can potentially provide large benefits in a vast array of clinical areas.
Further methodological development is needed to account for some types of endpoints.
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Background
In clinical trials gathering evidence about the effective-
ness of a medical intervention, it is necessary to specify a
primary endpoint. An endpoint should represent how
patients respond after being given the treatment; it
should be expected that the distribution of the endpoint
will be more favourable if a treatment is effective than if
it is ineffective. In many disorders it is difficult to specify
just one endpoint, as an intervention may have a variety
of effects that cannot be adequately measured through
one measurement. For this reason, it is common in
many conditions to combine multiple distinct endpoints
(which we will refer to as components) into a composite
endpoint.
Composite endpoints have been recommended when
there is large variability in the disease manifestation, e.g.
in complex multisystem diseases, allowing multiple
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equally relevant outcomes to be considered without the
need to correct for multiplicity. They have also been ad-
vocated for rare diseases, where they might improve the
power by increasing the number of events observed. On
the other hand, composite endpoints have been criticised
for making trial results more difficult to interpret [1].
One specific type of composite endpoint is a composite
responder endpoint, which divides patients into responders
and non-responders on the basis of the set of components.
Some of these components may be binary (present or
absent), and some may be continuous. In the case of con-
tinuous components, some dichotomisation is necessary, so
that patients are responders only if the continuous compo-
nent is above or below a specified threshold. In Table 1, we
provide examples of some commonly used responder-
based endpoints and their definitions. In some cases (such
as tumour response in Table 1) a patient must meet all the
criteria to be a responder; in other cases a patient must
meet a set number. Some responder endpoints are not
composite and are just formed from a single dichotomised
continuous endpoint.
Responder endpoints are appealing, as they simplify
several (potentially complex) pieces of information into
one responder/non-responder variable. The proportion of
patients who are responders serves as an easy-to-interpret
measurement of the effectiveness of a treatment.
From a statistical point of view, however, this ap-
pealing simplicity comes at a non-appealing cost
when one or more components are continuous.
Dichotomising continuous variables loses information,
a point which has been made several times (see, e.g.
[2–4]). This means that when considering one
continuous endpoint, it is substantially more efficient
to analyse it as a continuous variable rather than
dichotomise it and test it as a binary variable. As a
rule of thumb, the minimum cost of dichotomisation
is requiring a 35% higher sample size for the same
level of statistical precision [2].
Assuming that avoiding dichotomisation is desirable, it
is not obvious how this is possible when the responder
endpoint consists of a mix of continuous and binary
components. One method would be to use the ap-
proaches of Lachenbruch [5] or Hu and Proschan [6],
which use separate test statistics for each component
and form an overall test through appropriate weighting.
However, this technique loses the clinical interpretability
of the endpoint and does not allow efficient estimation
of the probability of response. Even in the case of a sin-
gle continuous component, there may be compelling
clinical reasons to keep a responder endpoint dichoto-
mised [7]: ease of interpretation to researchers and pa-
tients, wide acceptance as an important, meaningful
clinical diagnosis (e.g. diabetes or hypertension).
This motivates statistical methods that can be used to
keep what is clinically relevant by inferring the proportion
of patients who are responders, but also utilise informa-
tion contained in continuous components to improve the
efficiency. For the single-component responder, this idea
dates back to the 1990s, in studies where Suissa and Blais
[8, 9] proposed methods for doing this for a single con-
tinuous component case. To our knowledge, this method
rarely is applied in practice despite its advantages over
analysing the endpoint as binary. More recently, an ap-
proach known as the augmented binary method has been
developed that allows composite responder endpoints
(that consist of at least one continuous component) to be
analysed in a more efficient way, whilst maintaining the
definition of the endpoint.
In this paper (and its associated supplementary material)
we first describe the augmented binary method, focusing
on its advantages and drawbacks. The main novel contribu-
tion of the paper is a review that identifies new clinical
Table 1 Examples of responder endpoints used in different areas of medicine; italicised components denote continuous
dichotomisations. To be a responder, all numbered components are required to be met
Clinical area Endpoint Components and definitions
Oncology Tumour response 1. Sum of longest diameter of target tumour
lesions ≥ 30% shrinkage from baseline
2. No new tumour lesions
Rheumatology ACR20 1. Swollen joint count ≥ 20% improvement
2. Tender joint count ≥ 20% improvement
3. 20% improvement in at least three of:
a. Patient assessment
b. Physician assessment
c. Pain scale
d. Disability/functional questionnaire
e. Acute phase reactant (ESR or CRP)
4. No rescue therapy given
Type II diabetes Diabetes remission 1. Glycated haemoglobin A1c concentration ≤ 6.5%
2. Fasting glucose concentration≤ 5.6 mmol/L
3. No non-study pharmacological treatment given
ACR20 American College of Rheumatology 20% improvement, ESR erythrocyte sedimentation rate, CRP C-reactive protein
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areas where trial efficiency can be improved through use of
the augmented binary method. Finally, we discuss some
further developments to the method that are motivated by
the review.
The augmented binary method: intuition, benefits
and drawbacks
The augmented binary method extends previous work
focused on a single dichotomised continuous endpoint
[8, 9] to composite responder endpoints with a mix-
ture of continuous and binary endpoints. The original
motivation was solid tumour oncology [10, 11], but
subsequent papers have focused on developing the
methodology for rheumatology [12] and rare diseases
using composite endpoints [13].
For simplicity we focus on the case of a composite
responder endpoint that combines a dichotomised con-
tinuous component with a binary component. For ex-
ample, response in solid tumour oncology consists of
the sum of target lesion diameters shrinking by at least
30% from a baseline scan (dichotomised continuous)
and no new tumour lesions appearing on a scan (binary).
The traditional, binary analysis would work with the data
on whether or not each patient is a responder or not. If
a patient meets the criteria, he/she is a responder, other-
wise not. If analysing a randomised controlled trial
(RCT), then one might test for a difference between
arms in the proportion of patients who are responders
with an established method that gives an effect size, con-
fidence interval and p value (e.g. logistic regression).
A detailed description of how to fit the method is pro-
vided in the supplementary material, including R code
that can be used for the case of a composite responder
endpoint formed from a single continuous and single
binary component. The main intuition behind the
method is to first fit a more sophisticated model to the
data from the different components, and second to use
this model to estimate a probability of response and test
for a difference between arms. The second step can be
thought of as weighting the different patients as a pro-
portion of a response with this proportion depending on
how close the continuous component was to the thresh-
old. This is demonstrated in Fig. 1, which shows how
patients are measured on a continuous and a binary
component. The continuous measurement must be
above 1 for the patient to be a responder; however,
patients must also meet additional binary criteria. The
binary method treats the information as 0’s and 1’s,
whereas the augmented binary method uses a ‘response
weight’ which is determined from the underlying model
and is higher as the continuous component increases.
The supplementary material contains a link to an R
package that can be used to fit the model.
The benefit of the method is primarily the increased
power. By better using the available information, the
proportion of patients who respond (and therefore any
differences between arms in an RCT) can be estimated
more precisely. In more statistical language, the variance
of the estimate is lower, and the width of the confidence
interval (CI) is narrower. Simulation studies presented
by Wason and Seaman [10] found that the average gain
in power was equivalent to increasing the sample size by
at least 30%. The gain can be considerably higher de-
pending on the scenario, predominantly depending on
how well the dichotomisation point divides patients.
This gain in power has been confirmed by a re-analysis
Fig. 1 Illustration of how (hypothetical) response information from patients is weighted by the two different methods. Non-responders consist of
those in whom the continuous component is below 1 and those who do not respond according to another binary criterion. Underlying the
augmented binary method is a joint model that is fitted to the continuous and binary data and yields fitted ‘response weights’ for each patient;
these can then be compared between arms
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of the Oral Syk Inhibition in Rheumatoid Arthritis
(OSKIRA-1) trial [14], which showed that the reduction
in CI width was equivalent to an increase in sample size
of > 50% [12]. It should be emphasised that this gain in
power does not rely on additional data being collected—
it just comes from using the existing data more
efficiently.
There are some additional benefits of the approach.
First, due to the underlying model being fitted, it better
allows for missing data on different components [10] (it
is generally not obvious how to handle missing data on a
specific component of a composite outcome). This is
especially true when there is the possibility of some
components having more missing data than others. Sec-
ond, it may also help address issues of misclassification
due to measurement error: if a patient is truly close to
the responder threshold, then a measurement error will
have a potentially very large impact on the binary
method, but a small impact on the augmented binary
method.
There are also drawbacks. First, it is undoubtedly more
complex to apply the method compared with standard
binary approaches. Some code is available (see the sup-
plementary material) for applying the method in specific
cases, but a more generic implementation in different
commonly used statistical programs is a high priority for
the future. Second, the method makes more assump-
tions, for instance that the distribution of the continuous
components is normal. This means that it is necessary
to check this prior to analysing the data and use a suit-
able correction if assumptions are not met, such as ap-
plying a Box-Cox transformation [15] to ensure that the
continuous component is normally distributed. Third, if
the number of components or number of timepoints at
which the endpoint is measured is large, applying the
method can require a large amount of computational
time. This is generally not an issue for an analysis of a
single trial; however, assessing the performance of the
method on a large number of computer simulations can
become infeasible.
Up to now, the method has been applied to datasets in
solid tumour oncology [10, 11], rheumatoid arthritis [12]
and systemic lupus erythematosus (SLE) [16]. Based on
our personal experience of peer-reviewing clinical trial
papers and discussion with a wider group of clinicians,
we hypothesised that there might be a much greater
number of diseases where the augmented binary method
could be useful. We decided that a more systematic at-
tempt to identify these clinical areas was warranted.
Materials and methods
We made use of the COMET (Core Outcome Mea-
sures in Effectiveness Trials) database (http://www.
comet-initiative.org/resources), which lists completed
and ongoing projects in core outcome set (COS) de-
velopment. The COS represents the minimum that
should be measured and reported in all clinical trials
of a specific condition [17, 18].
We reviewed physiological and mortality trial outcomes
(categorised according to [19]) recorded within all COSs
in the COMET database that were published before 2016.
The restriction to 2016 allowed us to utilise the COS tax-
onomy presented in Dodd et al. [19], which considered
COSs up until then. This led to 287 COS papers to review,
which were split amongst the three authors (JW, MMM
and SD) to review. Each COS paper was reviewed to de-
termine if any responder (composite or categorised con-
tinuous) endpoints were recommended for reporting in all
clinical trials within that condition. In some cases, a po-
tentially relevant endpoint was not clearly described in the
core outcome paper. In this case, we examined RCTs that
had used the endpoint to determine whether it was a suit-
able responder endpoint.
Results
This process allowed us to identify 39 clinical areas
(additional to solid tumour oncology, rheumatoid arth-
ritis and SLE) where the augmented binary method
could be utilised to gain efficiency. An additional 28
clinical areas had used responder endpoints formed from
a single categorised/dichotomised continuous variable.
Table 2 breaks down the number by clinical classifica-
tion. A full listing of these clinical areas is given in the
supplementary material. These are given by clinical clas-
sification in supplementary tables 1a–m.
The clinical classifications for which the method ap-
pears most useful in terms of number of endpoints are
rheumatology (11 found), non-solid tumour oncology
(10 found), neurology (9 found) and cardiovascular (8
found).
We note that this review was not systematic and it
represents a likely substantial underestimate of the num-
ber of clinical areas where suitable endpoints are used,
as our review only covered clinical areas which were
covered by a COS published by 2016. As an example,
Table 1 mentions type II diabetes and shows diabetes
remission would be a suitable endpoint; however, since
there was no associated COS published by 2016, it does
not appear in the identified clinical areas (although ges-
tational diabetes does).
Discussion
In this paper we have highlighted and summarised
previous statistical work on an efficient analysis ap-
proach called the augmented binary method, which
can be used to improve analysis of composite re-
sponder outcomes. The method allows retention of
clinically relevant endpoints whilst improving the
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power of analyses by an amount equivalent to a con-
siderable increase in sample size. As well as describ-
ing previous work, we have conducted a review of
new clinical areas for which the method could be
used. We have also provided a worked example of fit-
ting the model using publicly available R code in the
supplementary material.
Through our review of core outcome sets, we have
found numerous new disease areas where the augmented
binary method could be applied to gain power. We ac-
knowledge that many of the core outcome sets were de-
veloped before best practice guidance [20] existed, and
therefore their quality may differ. We also do not know
whether the augmented binary method is currently being
used in any areas; however, our intuition is that it is
not—due to the relatively low number of citations of the
methodological papers describing the method. We hope
that this paper may help improve the uptake of the
method.
Although the results indicate the widespread utility of
the method, there are several areas where further meth-
odological research is required to fully realise the pos-
sible benefits.
There are several endpoints which are typically
analysed using time-to-event methods. Many progres-
sion, remission and relapse endpoints are used, and
the time until such a negative event occurs is the
quantity of interest. Although the augmented binary
method is well developed for composite responder
outcomes that are analysed at a single timepoint or
longitudinally, further work is needed to apply it to
time-to-event outcomes.
In some cases, the composite responder outcomes are
particularly complex, with more than two components
and with response being defined as meeting some, but
not all, of the criteria. Recent work in this area [16]
shows that the potential efficiency gain is even larger in
this case. In addition, the method, with some modifica-
tion to the underlying latent variable model, could be
applied in the case of a categorised responder endpoint
with more than two levels.
We have focused on how the method can improve the
statistical power of trials. An alternative way to use this
improved power would be to reduce the sample size
needed for a target power level. A barrier to widespread
use of the method in this way is sample size estimation.
Methods for conducting sample size estimation for trials
using responder endpoints analysed using latent variable
models are developed in McMenamin et al. [21]. Barriers
to this include the requirement for pilot data to inform
the values used for the required parameters. Further
work on ensuring that these methods can be used in
practice, such as software that can be used in a wide var-
iety of situations, is a priority for future research.
Conclusions
In this paper we have shown that responder composite
outcomes are used as primary clinical trial endpoints in
many diseases. Analysing data from these trials using the
augmented binary approach would improve power
equivalent to increasing the sample size by at least 35%.
Further methods research is needed to improve time-to-
event analyses using these outcomes as events.
Table 2 Number of new clinical areas identified by classification; full list provided in supplementary material
Classification Number of conditions with suitable
composite responder endpoints
Number of conditions with single-variable
responder endpoints
Bleeding and transfusion 2 1
Cancera 6 4
Cardiovascular and circulation 5 3
Dentistry and vision 2 1
Gastroenterology 3 1
Infectious diseases 3 0
Lungs and airways 0 2
Mental health and addiction 3 1
Neurology 2 7
Orthopaedics and trauma 1 3
Renal and urology 2 1
Rheumatology 8 3
Unclassified 2 1
Total 39 28
If a condition had both composite and non-composite responder endpoints identified, they were only included in the composite column
aExcludes solid tumour oncology (as the utility of the method had previously been highlighted there)
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